as 05-20-2024 10:30am EST
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. Its PDC therapeutic, iopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells.
Founded: | 2002 | Country: | United States |
Employees: | N/A | City: | FLORHAM PARK |
Market Cap: | 119.4M | IPO Year: | N/A |
Target Price: | $20.00 | AVG Volume (30 days): | 969.9K |
Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -3.08 | EPS Growth: | N/A |
52 Week Low/High: | $1.43 - $4.45 | Next Earning Date: | 05-14-2024 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
CLRB Breaking Stock News: Dive into CLRB Ticker-Specific Updates for Smart Investing
Thomson Reuters StreetEvents
5 days ago
GuruFocus.com
5 days ago
GlobeNewswire
6 days ago
GlobeNewswire
12 days ago
GlobeNewswire
13 days ago
Simply Wall St.
2 months ago
Insider Monkey
2 months ago
Thomson Reuters StreetEvents
2 months ago